Independent Expert Validates Medicus Pharma’s Phase 2 Clinical Data

Medicus Pharma (NASDAQ: MDCX) has received an independent endorsement from a dermatology expert regarding its Phase 2 clinical trial data for the SkinJect program. The program utilizes patent-protected microneedle arrays designed for the non-invasive treatment of basal cell carcinoma. This external validation confirms the accuracy of the topline results previously released by the company, strengthening its clinical standing. CEO Raza Bokhari emphasized that the expert’s review provides additional credibility to the efficacy of their novel skin disease treatment. The company aims to offer a less invasive alternative to traditional surgical methods for non-melanoma skin cancers. While the endorsement is a positive milestone for clinical credibility, the market impact is expected to be moderate as the core data was disclosed earlier this month.